Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy.
William J SandbornP RutgeertsC GasinkD JacobsteinB ZouJ JohannsB E SandsStephen HanauerS TarganSubrata GhoshW J S de VilliersJean Frederic ColombelBrian G FeaganPublished in: Alimentary pharmacology & therapeutics (2018)
Subcutaneous ustekinumab maintained clinical response and remission through Week 92. No new safety signals were observed. ClinicalTrials.gov number NCT01369355.